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Technologies for introducing molecules into living cells are vital for
probing the physical properties and biochemical interactions that
govern the cell’s behavior. Here, we report the development of a
nanoscale cell injection system (termed the nanoinjector) that uses
carbon nanotubes to deliver cargo into cells. A single multiwalled
carbon nanotube attached to an atomic force microscope (AFM) tip
was functionalized with cargo via a disulfide-based linker. Pene-
tration of cell membranes with this ‘‘nanoneedle’’ was controlled
by the AFM. The following reductive cleavage of the disulfide
bonds within the cell’s interior resulted in the release of cargo
inside the cells, after which the nanoneedle was retracted by AFM
control. The capability of the nanoinjector was demonstrated by
injection of protein-coated quantum dots into live human cells.
Single-particle tracking was used to characterize the diffusion
dynamics of injected quantum dots in the cytosol. This technique
causes no discernible membrane or cell damage, and can deliver a
discrete number of molecules to the cell’s interior without the
requirement of a carrier solvent.
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Technologies for introducing exogenous materials into cellsplay a central role in experimental cell biology. The major
challenge is to overcome the barrier imposed by the plasma
membrane. This challenge has been addressed in a variety of
ways, such as permeabilization of the membrane with lipids,
electric currents, or pore-forming toxins, and physical penetra-
tion with a micropipette (i.e., microinjection) or microprojectile
(1). Each method has its advantages and disadvantages, but one
common liability is physical damage to the cell membrane.
To overcome this problem, we sought to develop an alternative
method of intracellular delivery that combines the microinjec-
tion concept with emerging tools from nanotechnology. We
envisioned a ‘‘nanoinjector’’ that would penetrate cell mem-
branes with minimal perturbation, delivering cargo to the cell’s
interior with high spatial resolution (at the nanometer scale).
The proposed technology comprised three essential compo-
nents: a needle with nanoscale diameter, a manipulator with
nanoscale resolution, and controllable loading and releasing of
cargo. Here, we report the construction and successful operation
of a cell nanoinjector in which a single multiwalled carbon
nanotube (MWNT) attached to an atomic force microscope
(AFM) tip served as the ‘‘nanoneedle’’ and in which an AFM
integrated with an inverted fluorescence microscope served as
the nanomanipulator (Fig. 1).
Results and Discussion
With needle-like geometry, large Young’s modulus and high
tensile strength (2, 3), carbon nanotubes (CNTs) are ideal
nanoscale needles for this purpose. Their diameters can be
selected from a range of 1–20 nm, a scale that allows physical
penetration of a cell’s membrane without significant disruption
of the cell’s macrostructure. Indeed, such a piercing, which is on
the scale of a single protein’s diameter, should readily heal by
lipid diffusion without perturbation of the cytoskeleton (4).
Already, CNTs have demonstrated utility as cell transfection
reagents and membrane penetrating delivery vehicles (5–8).
The nanomanipulation system was based on a commercially
available AFM (MFP-3D-BIO; Asylum Research, Santa Bar-
bara, CA) that integrates an inverted fluorescence microscope
(Nikon Eclipse TE2000-U). The AFMplatform was ideal for this
application, as it offers control of nanoneedle displacement at
nanometer scale resolution and the ability to apply and monitor
forces on the cell membrane. Thus, the AFM enabled precise
positioning of the nanoneedle and high sensitivity monitoring of
the membrane-piercing event.
The MWNT-AFM tips used in this work were fabricated as
described (9). In brief, an individual MWNT of 10–20 nm in
diameter was retrieved from a metal foil by the AFM tip by using
a nanomanipulator inside a scanning electron microscope
(SEM). The MWNT was then cut to the desired length (0.5–1.5
m) by using an electron beam or electrical current. SEM and
transmission electron microscopy (TEM) images of one repre-
sentative MWNT-AFM tip are shown in Fig. 2 A and B,
respectively.
For the controlled loading and release of cargo, we aimed to
design a system that would obviate the need for a carrier solvent
and, accordingly, the addition of excess volume to the cell’s
cytosol during the injection process. Toward this end, we ex-
ploited established chemical methods for CNT surface modifi-
cation (10) and the intrinsic difference in redox potential be-
tween the intracellular and extracellular environments (11).
Compound 1 (Fig. 3) fulfilled the functions of cargo loading and
release as follows. Its pyrene moiety binds strongly to CNT
surfaces by means of – stacking (12). Compound 1 is also
endowed with a biotin moiety, separated from the pyrene group
via a disulfide bond. In the relatively oxidizing environment of
the cell’s exterior, the disulfide is stable. However, once exposed
to the reducing environment of the cytosol, the disulfide is
cleaved, liberating attached cargo. The kinetics of disulfide bond
cleavage within mammalian cells has been extensively studied,
allowing prediction of release rates during the nanoinjection
process (11, 13, 14).
To demonstrate the function of the nanoinjector, we sought to
deliver quantum dots to the cell’s cytosol without concomitant
membrane and cell damage, effects that are hard to avoid with
conventional delivery technologies (1). Quantum dots have
emerged as powerful optical probes for single particle and single
molecule studies in cellular systems (15). Their bright fluores-
cence and resistance to photobleaching have enabled single-
particle tracking of membrane proteins on the cell surface (16)
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and vesicles within cells (17). Without a delivery vehicle, quan-
tum dots cannot access the cell’s cytosol and nuclei. Accordingly,
processes therein have been refractory to study using quantum
dot technology.
We coated the MWNT-AFM tip with compound 1 by coin-
cubation in methanol. The tip was then loaded with streptavidin-
coated quantum dots (QDot streptavidin; Invitrogen) via non-
covalent complexation of streptavidin with biotin in borate
buffer (Fig. 3A). The loaded MWNT-AFM tips were character-
ized by TEM. As shown in Fig. 2C, multiple QDot streptavidin
conjugates were successfully loaded onto a single MWNT func-
tionalized with compound 1 (up to several hundred per 1-M
tip). In a control experiment, MWNT-AFM tips were incubated
directly with QDot streptavidin without prior coating with
compound 1. In this case, no QDot streptavidin conjugates were
observed on the MWNT surface [see supporting information
(SI) Fig. 5].
The nanoinjection experiments were then carried out by using
cultured HeLa cells, a human cervical epithelial cancer cell line.
A target cell within the field of the optical microscope was
identified, as indicated by the arrow in Fig. 4B. The cantilever
was then positioned on top of the target cell and the scan size was
set to 0 nm. The deflection of the cantilever was measured with
a photodiode to monitor the displacement of the nanoneedle as
the MWNT-AFM tip approached the cell surface. After the
MWNT came into contact with the cell, the cantilever was
further lowered so that the MWNT nanoneedle penetrated the
membrane. The MWNT nanoneedle was then maintained inside
the cell for various periods of time to allow reductive cleavage of
disulfide bonds and release of QDot streptavidin conjugates.
After injection, the cantilever was retracted and the cell was
imaged by fluorescence microscopy.
As shown in Fig. 4, f luorescence intensity inside the target cell
indicated the release of quantum dots. QDot streptavidin con-
jugates were never observed in neighboring cells. We confirmed
that the released quantum dots were within the cell’s interior by
video microscopy analysis. Their mobility was limited to the
confines of the cell, where they exhibited slow diffusion and
Fig. 1. Schematic of the nanoinjection procedure. A MWNT-AFM tip with cargo attached to the MWNT surface via a disulfide linker penetrates a cell membrane.
After disulfide reduction within the cell’s cytosol, the cargo is released and the nanoneedle is retracted.
Fig. 2. Characterization of nanoneedles before and after loading the cargo. (A) SEM image of a MWNT-AFM tip. (B) TEM image of the tip region of A. (C) TEM
image of a MWNT-AFM tip coated with linker 1 and conjugated with QDot streptavidin.
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eventual immobilization, perhaps because of interactions with
organelle membranes or cytoskeletal fibers (SI Movie 1).
In a typical experiment, a 15- to 30-min incubation of the
nanoneedle inside the cell was sufficient for release of a detect-
able number of quantum dots (Fig. 4). This observation is
consistent with published disulfide reduction rates. Each quan-
tum dot possesses 15 streptavidin molecules and each strepta-
vidin molecule can bind four biotin moieties. Therefore, the
quantum dots are likely bound to MWNT surfaces via multiple
disulfide bonds. The complete reduction of four disulfides within
a protein molecule requires 15min to 1 h (13, 14), consistent with
the release kinetics that we observe in situ. Based on fluores-
cence intensity calibration experiments using free quantum dots
in solution, and the sensitivity of our fluorescence microscope,
we estimate that the fluorescence intensity in Fig. 4 represents
small clusters of quantum dots with a diameter of 50–100 nm
(i.e., 5–50 quantum dots depending on their arrangement).
To rule out the possibility that release of the QDot strepta-
vidin conjugates occurred by desorption of the pyrene moiety
from the MWNT surface rather than disulfide cleavage, we
loaded cargo onto the MWNTs using control compound 2 (Fig.
3B). This linker possesses pyrene and biotin moieties, but
replaces the disulfide bond with a polyethylene glycol (PEG)
spacer separating theMWNT and streptavidin binding elements.
We functionalized MWNT-AFM tips with compound 2 and then
loaded QDot streptavidin conjugates onto the nanoneedle. The
modified MWNT-AFM tips were analyzed by TEM and were
similar to MWNT-AFM tips bearing the disulfide-bound con-
jugates (see SI Fig. 6). Similar nanoinjection experiments were
carried out by using HeLa cells, but, in this case, no QDot
streptavidin conjugates were released (with 5 different
MWNT-AFM tips in 10 injection experiments) (see SI Fig. 7).
These results have two important implications. First, the release
mechanism depends on disulfide bond cleavage and is therefore
not simply due to desorption of the pyrene moiety from the
MWNT surface. Second, the requirement of disulfide cleavage
confirms that cargo release occurred within the reducing envi-
ronment of the cytosol.
Fig. 3. Functionalization of MWNT-AFM tips. (A) QDot streptavidin was attached to the MWNT surface although linker 1 containing a disulfide bond: (i) 1,
MeOH; (ii) QDot streptavidin, borate buffer. (B) QDot streptavidin was attached to the MWNT surface although linker 2 containing no disulfide bond: (iii) 2,
MeOH; (iv) QDot streptavidin, borate buffer.
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A limitation of many intracellular delivery technologies is the
harmful effects they exert on membranes and cells. Therefore, we
probed the effects of nanoinjection on membrane integrity and cell
viability using three assays: (i) the trypan blue exclusion assay (18),
(ii) the Calcein AM assay (19), and (iii) the Annexin V-FITC/
propidium iodide (PI) assay for apoptosis (20). In the trypan blue
assay, the dye was added immediately after cell nanoinjection and
the cells were monitored for10 h thereafter. No trypan blue
inclusion or reduction in cell viability was observed during this time
period (see SI Table 1). In the Calcein AM assay, the cells were
loaded with the fluorescent dye immediately before nanoinjection.
Similar to the previous results, we saw no evidence of compromised
membrane integrity for up to 10 h (see SI Fig. 8). Finally, nanoin-
jected cells showed no detectable staining with Annexin V-FITC or
PI up to 10 h after the event (see SI Fig. 9). Thus, nanoinjection does
not seem to induce apoptotic pathways in the cells. In some
Fig. 4. Nanoinjection of QDot streptavidin conjugates into a target HeLa cell. (A) Fluorescence image of the cells before nanoinjection. (B) Combined bright-field
and fluorescence image of the cells before nanoinjection. The inserted arrow indicates the target cell. The dark shape in the lower left corner is the AFM cantilever.
(C) Fluorescence image of the cells after the nanoinjection, showing fluorescent QDot streptavidin conjugates released inside the target cell. (D) Combined bright-field
and fluorescence image of the cells after the nanoinjection. The QDot streptavidin conjugates are shown in red. The dark shape in the upper left corner is the retracted
AFM cantilever. (E) Combined bright-field and fluorescence image of another four examples of HeLa cells after nanoinjection of QDot streptavidin. In all cases,
fluorescence images were acquired with ex 415 nm and data collection with a 655-nm filter. Images are 70 70 m in A–D and 30 30 m in E.
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experiments, we held the nanoneedle inside the cell for 1 h
without any visible effect on membrane integrity and cell viability.
By contrast, a microinjection needle must typically be retracted
within seconds of injection to avoid cell damage (21). Notably, the
biocompatibility of nanoinjection should allow for exploration of a
broad range of release chemistries that occur over extended time
periods.
The ability to deliver quantum dots to the cell’s cytoplasm
provides a platform for numerous studies of intracellular pro-
cesses. As an example, we used the single-particle tracking
technique (16, 17, 22) to characterize the diffusion dynamics of
injected quantum dots in the cytosol, which has been previously
studied by using methods that can harm cells (23). After
nanoinjection, the diffusion dynamics of cytosolic quantum dots
were characterized by analyzing the mean square distance (r2)
and traveling time (t) for an injected quantum dot cluster (see
SI Fig. 10). The slope of the best-fit line afforded a diffusion
coefficient of 0.3 m2/s. This value is 10-fold lower than
diffusion coefficients measured in pure water, which is consistent
with previous measurements (23). A major advantage of the
biocompatible nanoinjection technology is that the process can
be performed repeatedly, or in tandem with other measure-
ments, throughout the normal life cycle of the cell.
In summary, the nanoinjector provides a mechanism for deliv-
ering a discrete, small number of molecules into cells without need
for carrier solvent and with no apparent cell damage. The unique
capabilities of the nanoinjector can be further exploited in a number
of ways. Other biomolecules such as DNA and RNA, or synthetic
structures such as polymers, dendrimers and nanoparticles can be
delivered into cells in a similar fashion. In conjunction with or-
ganelle-specific optical probes, the nanoinjector concept might be
extended to the delivery of cargo to specific subcellular compart-
ments. In principle, cells such as bacteria that are too small for
microinjection should be amenable to nanoinjection. Notably, the
architecture of the nanoinjector allows the use of AFM to identify
a target cell and position the nanoneedle, and is therefore not
limited by the resolution of light microscopy.
Materials and Methods
Materials. All chemical reagents were of analytical grade, ob-
tained from commercial suppliers and used without further
purification. The synthetic procedure of compounds 1 and 2 is
described in detail in SI Text.
Fabrication of MWNT-AFM Tips. The fabrication of MWNT-AFM
tips was carried out in an FEI Sirion XL 30 SEM, equipped with
a homemademanipulator. The procedure was described in detail
in a previous publication (9).
SEM and TEM Characterization. SEM images of MWNT-AFM tips
were obtained on an FEI Sirion XL 30 SEM operated at 5 keV.
TEM images of unfunctionalized and functionalized MWNT-
AFM tips were obtained on a JEOL 2011 microscope operating
at an electron energy of 100 keV. A homemade holder was used
for loading MWNT-AFM tips.
Functionaliztion of MWNT-AFM Tips. QDot 655 streptavidin conju-
gates (1 M solution, purchased from Invitrogen) were centri-
fuged at 5,000  g, reserving the supernatant, before use. The
MWNT-AFM tips were incubated with linker 1 or 2 (1 M,
MeOH) at room temperature for 1 h, followed by washing three
times with methanol and borate buffer (50 mM, pH 8.3),
respectively. The MWNT-AFM tips functionalized with 1 or 2
were then incubated with blocking buffer (borate buffer con-
taining 1% BSA) for 30 min. The blocked MWNT-AFM tips
were then transferred to a solution of QDot 655 streptavidin
conjugates (1:25 dilution) in borate buffer and incubated at room
temperature for 30 min, followed by washing three times with
borate buffer. The functionalized MWNT-AFM tips were then
used directly for nanoinjection experiments or dried under N2 for
TEM characterization. In a control experiment, the MWNT-
AFM tips were incubated with blocking buffer for 30 min. The
blocked MWNT-AFM tips were then transferred to a solution of
QDot 655 streptavidin conjugates (1:25 dilution) in borate buffer
and incubated at room temperature for 30 min, followed by
washing three times with borate buffer. The MWNT-AFM tips
were then dried under N2 for TEM characterization.
Cell Culture Conditions. HeLa cells were grown in DMEM sup-
plemented with penicillin (100 units/ml), streptomycin (0.1
mg/ml), and 10% FCS and maintained in a 5% CO2, water-
saturated atmosphere at 37°C.
Cell Viability Studies. The HeLa cells after nanoinjection were
studied by using three cell viability assays: trypan blue exclusion
assay, Calcein AM assay, and Annexin V-FITC/propidium io-
dide assay. The experimental procedures are described in detail
in SI Text.
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